JAK inhibitors for alopecia areata: a systematic review and meta-analysis.
💡 한 문장 핵심
원형탈모증에 대한 JAK 억제제: 체계적 문헌고찰 및 메타분석.
메타분석
5/5 보강
TL;DR
Oral route was significantly associated with response to treatment compared to topical therapy, and no difference was found between paediatric and adult cases in proportion of responses.
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
289 cases, there were 72.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
There is promising low-quality evidence regarding the effectiveness of JAK inhibitors in AA. Future large-sized randomized studies are required to confirm findings.
📑 코퍼스 인용 관계
· 인용됨 70
📑 인용한 논문 (6) ▾
- Retrospective Analysis of Oral Tofacitinib Treatment for Alopecia Areata at a Tertiary Car… Cureus · 2026
- Stem cell-based therapies for alopecia areata: a narrative review. Stem cell research & therapy · 2026
- Performance exploration of multi-gene panels of alopecia areata susceptibility and drug-bi… Frontiers in physiology · 2025
- A case of refractory alopecia areata successfully treated by combining delgocitinib ointme… Skin health and disease · 2025
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies. MedComm · 2025
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for mod… Frontiers in medicine · 2025
연도별 인용 (2019–2026) · 합계 198
OpenAlex 토픽 ·
Hair Growth and Disorders
Autoimmune Bullous Skin Diseases
Cutaneous lymphoproliferative disorders research
🇰🇷 한글 요약 🌐 Abstract
【연구 목적】
원형 탈모증(alopecia areata, AA)에 대한 JAK 억제제(tofacitinib, ruxolitinib, baricitinib) 치료 반응률과 반응·재발에 영향을 주는 인자를 규명하기 위한 체계적 문헌고찰 및 메타분석.
【방법】
PRISMA 가이드라인에 따른 체계적 문헌고찰 및 메타분석. 총 30개 연구, 289례를 분석하여 치료 반응률, 모발 재성장까지 소요 시간, 재발률 및 영향 인자(투여 경로, 연령군)를 평가.
【주요 결과】
전체 반응률 72.4%(양호한 반응 45.7%, 부분 반응 21.4%), 초기 발모까지 평균 2.2개월, 완전 재성장까지 6.7개월 소요. 재발 37례는 모두 치료 중단 후(평균 2.7개월) 발생했으며, 경구 투여가 국소 도포보다 유의하게 높은 반응률을 보였고, 소아·성인 간 반응률 차이는 없었음.
【임상적 시사점 (성형외과 의사 관점)】
모발이식(hair transplantation) 적응증이 어려운 광범위·중증 원형 탈모증 환자에서 JAK 억제제(특히 경구 제형)는 의뢰·병행 치료 옵션으로 고려할 수 있으며, 환자 상담 시 약 2개월 내 발모 시작·6~7개월 완전 재성장이라는 현실적 기대치를 제시할 수 있음. 다만 중단 시 재발 위험이 높아 장기 유지요법이 필요하다는 점과 근거 수준이 낮다는 한계를 함께 안내해야 함.
There have been a number of case reports and small clinical trials reporting promising outcomes of Janus Kinase (JAK) inhibitors tofacitinib, ruxolitinib and baricitinib for alopecia areata (AA). The majority of the literature to date is based on small volume data, with a lack of definitive evidence or guidelines. To determine the expected response of AA to JAK inhibitor therapy and factors which influence response and recurrence rates. A systematic review and meta-analysis was performed according to PRISMA guidelines. From 30 studies and 289 cases, there were 72.4% responders, good responders 45.7% and partial responders 21.4%. Mean time to initial hair growth was 2.2 ± 6.7 months, and time to complete hair regrowth was 6.7 ± 2.2 months. All 37 recurrences occurred when treatment was ceased after 2.7 months. Oral route was significantly associated with response to treatment compared to topical therapy. No difference was found between paediatric and adult cases in proportion of responses. There is promising low-quality evidence regarding the effectiveness of JAK inhibitors in AA. Future large-sized randomized studies are required to confirm findings.
- 연구 설계 systematic review
【연구 목적】 원형 탈모증(alopecia areata, AA)에 대한 JAK 억제제(tofacitinib, ruxolitinib, baricitinib) 치료 반응률과 반응·재발에 영향을 주는 인자를 규명하기 위한 체계적 문헌고찰 및 메타분석.
APA 7
Phan, K., & Sebaratnam, D. F. (2019). Jak inhibitors for alopecia areata: A systematic review and meta-analysis.. Journal of the European Academy of Dermatology and Venereology : JEADV, 33(5), 850-856. https://doi.org/10.1111/jdv.15489
Vancouver
Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. Jour. Euro. Acad. Derm. Vene. : JEAD.. 2019;33(5):850-856. doi:10.1111/jdv.15489
AMA 11
Phan K, Sebaratnam DF. JAK inhibitors for alopecia areata: a systematic review and meta-analysis. Jour. Euro. Acad. Derm. Vene. : JEAD.. 2019;33(5):850-856. doi:10.1111/jdv.15489
Chicago
Phan, K., and Sebaratnam, D. F.. 2019. "JAK inhibitors for alopecia areata: a systematic review and meta-analysis." Journal of the European Academy of Dermatology and Venereology : JEADV 33 (5): 850-856. https://doi.org/10.1111/jdv.15489
MLA 9
Phan, K., and Sebaratnam DF. "JAK inhibitors for alopecia areata: a systematic review and meta-analysis." Journal of the European Academy of Dermatology and Venereology : JEADV, vol. 33, no. 5, 2019, pp. 850-856. doi:10.1111/jdv.15489.
PMID
30762909 ↗
추출된 의학 개체 (NER)
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 | |
| 질환 | alopecia areata
|
원형 탈모증 | dict | 2 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
인용 관계
그래프 OA 노드: 6/8 (75%)
· 참조 0편 · 후속 6편
이 논문을 인용한 후속 연구 20
- Alopecia Areata: an Update on Etiopathogenesis, Diagnosis, and Management.
- Phase 2a randomized clinical trial of dupilumab (anti-IL-4Rα) for alopecia areata patients.
- Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuo…
- Alopecia Areata: Current Treatments and New Directions.
- The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis…
- Alopecia Areata: An Updated Review for 2023.
- Baricitinib for the Treatment of Alopecia Areata.
- A Comprehensive Literature Review of JAK Inhibitors in Treatment of Alopecia Areata.
- Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs.
- Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
- New and Emerging Therapies for Alopecia Areata.
- Upadacitinib improved alopecia areata in a patient with atopic dermatitis: A case report.
- A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitin…
- Alopecia areata susceptibility variant in MHC region impacts expressions of genes contributing to ha…
- An Updated Review on Current Treatment of Alopecia Areata and Newer Therapeutic Options.
- Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to…
- Cyclosporine With and Without Systemic Corticosteroids in Treatment of Alopecia Areata: A Systematic…
- Alopecia Areata: Pathogenesis, Diagnosis, and Therapies.
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Rev…
같은 제1저자의 인용 많은 논문 (5)
- Methotrexate for alopecia areata: A systematic review and meta-analysis.
- Methotrexate in the treatment of paediatric alopecia areata: Retrospective case series and updated meta-analysis.
- Botulinum Toxin for Scalp Dysesthesia.
- Autologous Fat Grafting for Plantar Fasciitis.
- Emerging off-label esthetic uses of botulinum toxin in dermatology.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
-
Alopecia areata.
TL;DRAlopecia areata is difficult to manage medically, but recent advances in understanding the molecular mechanisms have revealed new treatments and the possibility of remission in the…
-
Epidemiology and burden of alopecia areata: a systematic review.
TL;DRAA is the most prevalent autoimmune disorder and the second most prevalent hair loss disorder after androgenetic alopecia, and the lifetime risk in the global population is approxi…
-
Two Phase 3 Trials of Baricitinib for Alopecia Areata.
TL;DRIn two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.
-
Treatment options for androgenetic alopecia: Efficacy, side effects, compliance, financial considerations, and ethics.
TL;DRAlthough a variety of medical, surgical, light‐based and nutraceutical treatment options are available to slow or reverse the progression of AGA, it can be challenging to select ap…
-
Hair follicle immune privilege and its collapse in alopecia areata.
TL;DRA key goal for effective AA management is the re‐establishment of a functional HF IP, which will also provide superior protection from disease relapse, and may confer increased sus…